Does adjuvant letrozole reduce uterine peristalsis prior to fresh embryo transfer?

Marianne Dreyer Holt, Agnieszka Katarzyna Warzecha, Nathalie Søderhamn Bülow, Sven Olaf Skouby, Anne Lis Mikkelsen Englund, Kathrine Birch Petersen, Nicholas Stephen Macklon, Marianne Dreyer Holt, Agnieszka Katarzyna Warzecha, Nathalie Søderhamn Bülow, Sven Olaf Skouby, Anne Lis Mikkelsen Englund, Kathrine Birch Petersen, Nicholas Stephen Macklon

Abstract

Study question: Does adjuvant letrozole in ovarian stimulation for IVF decrease the uterine peristalsis frequency (UPF) prior to fresh embryo transfer (ET)?

Summary answer: Adjuvant letrozole in ovarian stimulation for IVF does not reduce the UPF significantly prior to fresh ET.

What is known already: Throughout the cycle, uterine peristalsis aids spermatozoa transport to the fallopian tube and may affect implantation. At fresh ET, UPF is negatively correlated with implantation and clinical pregnancy rates and is believed to be modulated by oestradiol and progesterone. High levels of oestradiol, from multiple follicular development, in ovarian stimulation have been reported to increase UPF, whereas progesterone is considered to be an utero-relaxant. The influence of androgens is unclear. Co-treatment with letrozole during gonadotropin ovarian stimulation limits the supra-physiological oestradiol rise and may therefore reduce UPF prior to fresh ET.

Study design size duration: This study was carried out on subjects participating in a single-centre double-blinded randomized controlled trial of the impact of letrozole on follicle development and endocrine profiles, and investigated the impact of adjuvant letrozole in ovarian stimulation for IVF on UPF prior to fresh ET and the correlations of UPF with endocrine markers. Between 2016 and 2017, 39 women expected to be normal responders were randomized to co-treatment with letrozole or placebo. Of these, 33 women completed this element of the study. The study was carried out according to the Helsinki Declaration and the ICH-Good-Clinical-Practice.

Participants/materials setting methods: Eligible women were randomized 1:1 to adjuvant treatment with letrozole 5 mg/day or placebo in an antagonist protocol using a fixed dose of recombinant (r) FSH 150 IU/day. Final maturation was triggered with hCG 6500 IU and luteal support with vaginal progesterone was administered from the day following oocyte aspiration. Less than 1 h prior to fresh ET, 6-min duration transvaginal ultrasound recordings of the uterus in sagittal section were performed and blood samples were drawn.

Main results and the role of chance: A total of 33 women completed the study (letrozole n = 17; placebo n = 16). Age, BMI and ovarian reserve markers were similar between the groups. On the day of ET, serum oestradiol levels were significantly suppressed in the letrozole group to a mean of 867 ± 827 pmol/l compared to 3110 ± 1528 pmol/l in the placebo group (P < 0.001). Mean UPF prior to fresh ET did not differ between the intervention and placebo group (3.3 ± 0.36 versus 3.5 ± 0.51 per minute respectively, P = 0.108). UPF was assessed and agreed by two observers who were blinded to adjuvant treatment. Two patients were excluded due to poor quality of the ultrasound recordings. Supra-physiological serum oestradiol in the placebo group were negatively correlated with UPF (P = 0.014; R = -0.62), but the more physiological serum oestradiol levels in the letrozole group showed no correlation with UPF (P = 0.567; R = 0.15). Serum progesterone levels were similar in both groups and did not show any significant correlation with UPF. Testosterone levels were significantly higher in the letrozole group (P = 0.005) and showed a non-significant trend that negatively correlated with UPF in the placebo group (P-value = 0.071, R = -0.48).

Limitations reasons for caution: Limitations of the study included the limited sample size and the lack of a power calculation specifically determined for this endpoint.

Wider implications of the findings: The supra-physiological levels of oestradiol generated during ovarian stimulation were significantly suppressed in the intervention group. However, UPF prior to fresh ET was similar in both groups. Modulating the luteal phase sex steroids with adjuvant letrozole had little measured impact on UPF. Any beneficial effect of adjuvant letrozole during ovarian stimulation is unlikely to be due to significant modulation of UPF.

Study funding/competing interests: M.D.H.'s salary was funded by an unrestricted research grant from Gedeon Richter. The expenses of the study were funded by a scientific collaboration: ReproUnion, co-financed by the European Union, Interreg Öresund-Kattegat-Skagerrak and Ferring Pharmaceuticals. The assays for the analyses were funded by Roche Diagnostics and an unrestricted research grant from Merck Life Science AS, Denmark. The authors have no competing interests to declare regarding this study.

Trial registration number: Clinicaltrials.gov: NCT02939898, EudraCT no.: 2015-005683-41.

Keywords: assisted reproduction; endocrinology; endometrium; luteal phase; oestrogen; ovarian stimulation; progesterone; ultrasound.

© The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology.

Figures

Figure 1.
Figure 1.
CONSORT flow diagram.
Figure 2.
Figure 2.
Uterine peristalsis frequency. The boxplot shows the uterine peristalsis frequency per minute in the placebo and letrozole group <1 h to fresh embryo transfer on Days 2, 3 or 5 after oocyte retrieval.
Figure 3.
Figure 3.
Hormonal levels. The boxplots show the serum hormonal levels in the placebo and letrozole group at the day of fresh embryo transfer on Days 2, 3 or 5 after oocyte retrieval. (A) Oestradiol. (B) Progesterone. (C) Testosterone. (D) Androstenedione.
Figure 4.
Figure 4.
Hormonal correlation with uterine peristalsis frequency. The scatter plots show the hormonal correlations with the uterine peristalsis frequency <1 h to fresh embryo transfer in the placebo and letrozole group on Days 2, 3 or 5 after oocyte retrieval. (A) Oestradiol. (B) Progesterone. (C) Testosterone. (D) Androstenedione.

References

    1. Bulletti C, de Ziegler D. Uterine contractility and embryo implantation. Curr Opin Obstet Gynecol 2005;17:265–276.
    1. Bulletti C, de Ziegler D, Polli V, Diotallevi L, Ferro ED, Flamigni C. Uterine contractility during the menstrual cycle. Hum Reprod 2000;15:81–89.
    1. Bülow NS, Dreyer Holt M, Skouby SO, Birch Petersen K, Englund AL, Pinborg A, Macklon NS. Co-treatment with letrozole during ovarian stimulation for IVF/ICSI—a systematic review and meta-analysis. Reprod Biomed Online 2022a. Doi: 10.1016/j.rbmo.2021.12.006.
    1. Bülow NS, Skouby SO, Warzecha AK, Udengaard H, Andersen CY, Holt MD, Grøndahl ML, Andersen AN, Sopa N, Mikkelsen ALE et al. Impact of letrozole co-treatment during ovarian stimulation with gonadotropins for IVF: a multicenter, randomized, double-blinded placebo-controlled trial. Hum Reprod 2022b;37:309–321.
    1. Casper R, Haas J, Hsieh TB, Bassil R, Mehta C. Recent advances in in vitro fertilization. F1000Res 2017;6:1616.
    1. Chung CHS, Wong AWY, Chan CPSl, Saravelos SH, Kong GWS, Cheung LP, Chung JPW, Li TC. The changing pattern of uterine contractions before and after fresh embryo transfer and its relation to clinical outcome. Reprod Biomed Online 2017;34:240–247.
    1. Eytan O, Halevi I, Har-Toov J, Wolman I, Elad D, Jaffa A. Characteristics of uterine peristalsis in spontaneous and induced cycles. Fertil Steril 2001;76:337–341.
    1. Fanchin R, Ayoubi J, Olivennes F, Righini C, de Ziegler D, Frydman R. Hormonal influence on the uterine contractility during ovarian stimulation. Hum Reprod 2000;15:90–100.
    1. Fanchin R, Ayoubi J, Righini C, Olivennes F, Schönauer LM, Frydman R. Uterine contractility decreases at the time of blastocyst transfers. Hum Reprod 2001a;16:1115–1119.
    1. Fanchin R, Righini C, de Ziegler D, Olivennes F, Ledee N, Frydman R. Effects of vaginal progesterone administration on uterine contractility at the time of embryo transfer. Fertil Steril 2001b;75:1136–1140.
    1. Fanchin R, Righini C, Olivennes F, Taylor S, de Ziegler D, Frydman R. Uterine contractions at the time of embryo transfer alter pregnancy rates after in-vitro fertilization. Hum Reprod 1998;13:1967–1974.
    1. Franik S, Eltrop SM, Kremer JA, Kiesel L, Farquhar C; Cochrane Gynaecology and Fertility Group. Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev 2018;5:CD010287.
    1. Griesinger G, Blockeel C, Pierzynski P, Tournaye H, Višňová H, Humberstone A, Terrill P, Pohl O, Garner E, Donnez J et al. Effect of the oxytocin receptor antagonist nolasiban on pregnancy rates in women undergoing embryo transfer following IVF: analysis of three randomised clinical trials. Hum Reprod 2021;36:1007–1020.
    1. Ijland MM, Evers JL, Dunselman GAJ, Hoogland HJ. Endometrial wavelike activity, endometrial thickness, and ultrasound texture in controlled ovarian hyperstimulation cycles. Fertil Steril 1998;70:279–283.
    1. Ijland MM, Evers JL, Hoogland HJ. Velocity of endometrial wavelike activity in spontaneous cycles. Fertil Steril 1997;68:72–75.
    1. Kamath MS, Maheshwari A, Bhattacharya S, Lor KY, Gibreel A. Oral medications including clomipheme citrate or aromatase inhibitors with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilization. Cochrane Database Syst Rev 2017;11:CD008528.
    1. Kuijsters NPM, Methorst WG, Kortenhorst MSQ, Rabotti C, Mischi M, Schoot BC. Uterine peristalsis and fertility: current knowledge and future perspectives: a review and a meta-analysis. Reprod Biomed Online 2017;35:50–71.
    1. Kuijsters NPM, Sammali F, Rabotti C, Huang Y, Mischi M, Schoot BC. Visual inspection of transvaginal ultrasound videos to characterize uterine peristalsis: an inter-observer agreement study. J Ultrasound 2020;23:37–44.
    1. Kunz G, Beil D, Deininger H, Wildt L, Leyendecker G. The dynamics of rapid sperm transport through the female genital track: evidence from vaginal sonography of uterine peristalsis and hysterosalpingoscintigraphy. Hum Reprod 1996;11:627–632.
    1. Kunz G, Noe M, Herbertz M, Leyendecker G. Uterine peristalsis during the follicular phase of the menstrual cycle: effects of oestrogen, antiestrogen and oxytocin. Hum Reprod Update 1998;4:647–654.
    1. Oike K, Ishihara K, Kikuchi S. A study of the endometrial movement and serum hormonal level in connection with uterine contraction. Nihon Sanka Fujinka Gakkai Zasshi 1990;42:86–92.
    1. van Gestel I, Ijland MM, Hoogland HJ, Evers JLH. Endometrial wave-like activity in the non-pregnant uterus. Hum Reprod Update 2003;9:131–138.
    1. Zhu L, Che HS, Xiao L, Li YP. Uterine peristalsis before embryo transfer affects the chance of clinical pregnancy in fresh and frozen-thawed embryo transfer cycles. Hum Reprod 2014;29:1238–1243.
    1. Zhu L, Li Y, Xu A. Influence of controlled ovarian hyperstimulation on uterine peristalsis in infertile woman. Hum Reprod 2012;27:2684–2689.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다